89 results on '"Rizzo, J. Douglas"'
Search Results
2. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
3. Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes
4. Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report from the BMT CTN Patient and Caregiver Advocacy Task Force
5. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]
6. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]
7. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry
8. COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum
9. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
10. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
11. Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol
12. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results
13. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting
14. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study
15. A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT).
16. Community Health Status and Its Association with Patient Outcome Post Allogeneic Hematopoietic Cell Transplantation [HS1]2500 Character Limit of Body of Abstract without Spaces or Title
17. Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation
18. IL-6 Is Not Significantly Associated with Quality of Life Symptoms in Allogeneic Hematopoietic Cell Transplant Recipients Following Tocilizumab
19. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
20. Peripheral Blood Grafts for T Cell–Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome
21. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
22. Genomic Mechanisms of SES-Related Outcome Disparities in Hematopoietic Cell Transplantation
23. Use of Propylene Glycol-Free Melphalan Conditioning in Light Chain Amyloidosis Patients Undergoing Autologous Hematopoietic Cell Transplantation is Associated with Significantly Lower Hospitalization Days
24. Propranolol Inhibits Stress-Related Gene Expression Profiles Associated with Adverse Clinical Outcomes in Autologous Hematopoietic Cell Transplantation Recipients
25. The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe)
26. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome
27. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation
28. National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report
29. Application of the CIBMTR Survival Outcomes Calculator to CD34-Selected Allogeneic HCT for Acute Leukemia and Myelodysplastic Syndrome
30. Results of a Phase II Clinical Trial of Tocilizumab, Tacrolimus and Methotrexate (Toc/Tac/MTX) for the Prevention of Acute Graft Versus Host Disease (GVHD) and Matched Case Control Comparison to Tac/MTX after Allogeneic Stem Cell Transplantation
31. Importance of Site Preparation in Reducing the Risk of Bacterial Contamination during Bone Marrow Harvest
32. Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902)
33. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial
34. Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)
35. Etanercept for Late Onset Idiopathic Pneumonia Syndrome
36. Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty) and Sex: Primary Analysis of the Pediatric Toxicity Cohort of the Related Donor Safety Study (RDSafe)
37. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study
38. National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery
39. Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation
40. Clinical Outcomes Among Unrelated Donor Transplant Recipients for Acute Myelogenous Leukemia As a Function of Socioeconomic Status and Related Transcriptome Differences
41. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): Impact of Disease Risk and Conditioning Regimen
42. Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors: Primary Analysis of the Related Donor Safety Study (RDSafe)
43. Patient and Provider Preferences for Survivorship Care Plans for Allogeneic Hematopoietic Cell Transplantation (HCT) Survivors: A Qualitative Study
44. Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study
45. Plerixafor and Abbreviated-Course Granulocyte Colony–Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis
46. Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902
47. Safety of Outpatient Autologous Hematopoietic Cell Transplantation (AuHCT) for Multiple Myeloma and Lymphoma
48. Extending the Bridg Model with Hematopoietic Cell Transplant Concepts
49. Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study (RDSafe)
50. Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.